[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

Aortech Share Discussion Threads

Showing 8351 to 8374 of 8900 messages
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
DateSubjectAuthorDiscuss
14/1/2020
15:06
Yes, thanks for views on TRX landy
the stigologist
14/1/2020
14:41
In the absence of any price action, it is worth (I find) keeping an eye on the general markets since, obviously, if we are entering a friendly market for smaller stocks, then we can expect individual shares to follow the general trend in the absence of specific drivers. I look at the FTSE AIM All-Share index from time to time since that is a solid indicator of sentiment in smaller AIM stocks. AOR has been volatile over the last two years but part of that action can be attributed to the sentiment governing the AIM All-Share. Https://www.londonstockexchange.com/exchange/prices-and-markets/stocks/indices/summary/summary-indices-chart.html?index=AXX In Jan 2016, it bottomed at under 700, partly because it contains a good number of O&G and the oil price had cratered by that date. However, by summer 2018, the index had hit 1100 (up 65%) after a long bull market in overall shares. Yet, from the end of Sep 2018 to Dec 2018, the AIM All-Share crashed to 850 in the space of three months. Since then, it recovered mildly to 970 and fell back again to 850 but is now back to 965 on an upward trend. If it breaks through, chartists may argue that the 2018 peak of 1100 is its next stop. If you compare AOR’s movement since the fund raise in June 2018 to the AIM All-Share, you will get a better picture of why the stock has moved up and down so violently. The crucial thing for me is that AOR has now surpassed its 2018 highs whereas the AIM All-Share has 15% to go before catching its previous peak of 1100. The outperformance of AOR can be attributed to its improving work on the device developments but has it really received anything like the credit it should for what has been achieved since 2018? I personally think not! I hope the positive AIM All-Share trend will translate into a magnified out-performance by AOR as its success will hopefully be recognised while new investors looking to board the bull market may also pick up the shares.
bones
14/1/2020
14:27
I agree with your views, GR. The following is taken from the interim report so, like you, I would expect some further news in the not too distant future. 'The recent pace of development of the large bore grafts and resulting prototype devices has been outstanding. Major developments have been achieved in the textile construction, heat setting and crimping technology, together with the application of Elast-Eon™ coating and sealant. Bringing all of this together has resulted in the recent production of a 100 per cent sealed, superb handling Aortic Root graft that retains its shape and form without being pressurised.'
langland
14/1/2020
10:49
The market ignored the substance in the last announcement. These are primed to move on the next textile update which I anticipate will be before the end of Q1. I've taken a few more as in my view this looks to have a great future and you need to buy when there is some stock around. Good luck all.
greedy rooster
13/1/2020
11:44
Thanks for clearing that up Landy.
semper vigilans
13/1/2020
11:37
The TRX valve is a homograft (ie a human heart valve)treated to remove donor cells, creating a scaffold for the patient to regenerate. Main area of interest is paediatric surgery for pulmonary valve. Not really a viable option for older patient with calcified aortic valve. Its a bit of a niche product.AorTech are looking at the wider market with a polymer valve that should also not calcify and have durability advantages.
landy90
13/1/2020
11:07
I think there may be some bigger names looking at it than us. I agree it would be diversion. Not unheard of for some big players to buy tech IP (which threatens their core business) but rather than develop it they just 'park it' to stop others developing it.
the stigologist
13/1/2020
10:41
Do you mean pick up the heart tissue stuff cheap if unfortunately TRX hits the buffers? Might become a cash drag or overload management time at AOr?
semper vigilans
13/1/2020
10:36
o/t yes TRX have said they only have cash runway to March 2020 seems extraordinary situation real technology, revenues etc but got itself into a hole with debt funding seems very binary outcome now However the heart tissue stuff seems super interesting from our perspective no ?
the stigologist
13/1/2020
10:22
Stigologist - I think it is tarnished by Woodford: products may be good but I think it needs more funding.
semper vigilans
12/1/2020
15:06
Anybody know anything about TRX seems an interesting business in same field? www.proactiveinvestors.com/companies/news/48670/tissue-regenix-to-present-dcell-at-prestigious-heart-valve-event-58000.html Tissue Regenix’s (LON:TRX) dCell technology is to be presented at a prestigious heart valve event in Venice, Italy. Internationally renowned cardiac surgeon Professor Francisco da Costa, one of the company’s long-term collaborators, will exhibit the findings of the company's flagship technology at the seventh Biennial Congress of the Society for Heart Valve Disease & Heart Valve Society of America on June 23. Antony Odell, Tissue Regenix’s managing director, said: “We are pleased to see recognition for dCELL heart valve technology by this internationally distinguished congress. It is an important step towards the company's commercialisation in this key area.” dCell allows human or animal tissue to replace damaged skin or body parts in other patients. So far, data amassed from a study on more than 400 patients over an eight-year period shows the body is more accepting of the new tissue, with particularly good results in younger patients. Other key findings include lower and stable gradients up to eight years, no calcification, and partial repopulation of the grafts.
the stigologist
09/1/2020
11:24
That 30k buy at the full ask of 95 explains the mark up this AM. I bought the early 6k and would have bought more but that was all that was available at the price.
langland
09/1/2020
10:24
It looks like we have mm's bidding for stock, Do they have orders to fill????? Who is buying??
7767
09/1/2020
08:28
The 89 has gone now. One buyer of 6k. Now 92 to buy. (It wasn’t me!)
bones
08/1/2020
15:43
I can buy at 0.8899
toffeeman
08/1/2020
15:25
TM, yes I know that, but it’s unusual for them to be almost on the bid for a purchase when the quoted spread is so wide. Usually when AOR is quoted as it is, 87-95 in this case, the usual prices you could get on an O trade would be, say, 89-93. It differs with demand/supply of course but to quote 87-95 when the true spread is 87-89 is very odd, as though they are trying to disguise the trading patterns. Anyway, I was only curious. An MM is probably just getting shot of the stock sold to it in the last two days. I’m moving on! Let it settle down and come back in February.
bones
08/1/2020
14:42
MM quotes are meaningless because they are all O trades. The spread is only indicative for AT stocks. With stocks like this you can always trade inside the spread.
toffeeman
08/1/2020
14:32
Current public MM quotes are 87-95 yet currently I can buy online at 89 (as someone just did with 5,750 of them). The price still seems to be available so what is going on with the 95 MM offer quotes??
bones
08/1/2020
10:24
Amt, yes but that is old news. Aortech said it was “circling back” to revisit the designs over a year ago. It has since been working on its new designs for the last year using the computerised design tools at its partner, VFT. From my outlook, the company has been refining and honing the heart valve designs for the last year with the aim of developing a superior polymer heart valve that can be mass produced by its own specially designed precision tooling and equipment and does not need each valve to be individually checked for quality as is the case with the dip casted current technology being trialled by Foldax. It is a big engineering challenge but the potential rewards are huge. Aortech has now finally got to the stage where they have a sufficient degree of confidence in the designs to order the specialist tooling to put the designs to the test for prototype production. The making of the decision to order the tooling upon satisfaction that the designs are as good as can be for now is the only new news here, I think. The heart valve has always been the highest risk/reward part of the Aortech projects. As Nimbo10 said, the grafts and patches project is a more immediate prospect and we will hopefully be updated as that progresses through prototype testing currently ongoing (as per trading update in November). Plus, we now have Medibrane also acting for the company in developing the IP licensing of Elasteon over time. Aortech has made it clear these projects all have long lead times. No instant karma here!
bones
08/1/2020
10:02
A new process increases the risks. It sounds like a fundamental change to me so surely some risk comes with that.
amt
08/1/2020
09:10
Seeing as the share price had more than doubled in the previous two months a bit of profit taking should not be unexpected. Now, lets bring on the next leg up.
someuwin
08/1/2020
08:20
Would be interesting to hear landy's take on the share price decline..related to the news flow, which could possibly delay first income streams or "just the way the market is"
25october1969
08/1/2020
07:45
An excuse to sell, that's what traders do. I too don't see anything that would make me run to the door. The grafts area is far more mature and developments have been going well from recent statements. Revenues from this may help with the funding for the longer term heart valve project, which is a long term game changer if it goes well.
nimbo10
08/1/2020
00:01
I am at a loss about why some investors have interpreted the latest heart valve development update as containing news of unexpected changes! The 29 November 2019 interims reported the following: “We are continuing to make good progress on both valve design and design for manufacture and feedback from the process is currently driving further improvements. We hope to commit soon to the manufacture of early proof of concept prototypes. This should confirm the capabilities of the novel manufacturing technology we are looking to adopt before finalising the design. The objective being to have design freeze quality valves under testing next year.” All that yesterday’s update did (as far as I can see) was confirm that the commitment to acquire the tooling necessary for the manufacturing of prototypes has now been made. In other words, the trigger has now been pulled for the expenditure to go ahead on the basis that the valve design and design for manufacture processes have advanced enough to make the company confident of those designs. Something that had not happened as of 29th November 2019 interims. The rest of yesterday’s RNS dealt with the historic reasons why Aortech believe that this new technology (which it has worked on all last year) is needed. This isn’t information that has just been discovered since the November interims. The updates all last year refer to the new novel technology being worked on. What I think has caused confusion is the layout of the information being relayed in the RNS. It is not necessarily clear to everyone where the past tense and the present tense separate. Maybe the RNS could have been ordered slightly differently so that the information in the middle of it (that the commitment has now been made to make the investment) followed immediately after the first paragraph that referred to the 29th November information? That’s the main thrust of the RNS after all. Then it might have followed that by explaining the historic background reasons for the change. That was useful information in itself and clearly the company thought it would be helpful to explain it. It also highlights the issues that the competitor Foldax may have to face which Aortech hopes to avoid by having a far superior new method of manufacture. I have followed this company for a long time so I did not see the confusion myself but I guess I can see why others have misinterpreted the detail about changing from a previous methodology as being a recent change. It is not recent and it is not new news, IMHO. Also, no one has ever suggested the heart valve project would be inexpensive. That is not new news either.
bones
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210917 09:36:48